Amylyx’s bet on a GLP-1 blocker pays off
A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.